PL1696947T3 - Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelit - Google Patents
Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelitInfo
- Publication number
- PL1696947T3 PL1696947T3 PL04803748T PL04803748T PL1696947T3 PL 1696947 T3 PL1696947 T3 PL 1696947T3 PL 04803748 T PL04803748 T PL 04803748T PL 04803748 T PL04803748 T PL 04803748T PL 1696947 T3 PL1696947 T3 PL 1696947T3
- Authority
- PL
- Poland
- Prior art keywords
- erythropoietin
- disturbances
- treatment
- chronic inflammatory
- intestinal diseases
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title 2
- 102000003951 Erythropoietin Human genes 0.000 title 1
- 108090000394 Erythropoietin Proteins 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 229940105423 erythropoietin Drugs 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 208000028774 intestinal disease Diseases 0.000 title 1
- 229910052742 iron Inorganic materials 0.000 title 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03104832 | 2003-12-19 | ||
| EP04803748.5A EP1696947B1 (en) | 2003-12-19 | 2004-12-10 | Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases |
| PCT/EP2004/014105 WO2005058347A1 (en) | 2003-12-19 | 2004-12-10 | Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1696947T3 true PL1696947T3 (pl) | 2014-08-29 |
Family
ID=34684610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04803748T PL1696947T3 (pl) | 2003-12-19 | 2004-12-10 | Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelit |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7459429B2 (pl) |
| EP (1) | EP1696947B1 (pl) |
| JP (1) | JP2007514673A (pl) |
| CN (1) | CN1901934B (pl) |
| CA (1) | CA2549486C (pl) |
| DK (1) | DK1696947T3 (pl) |
| ES (1) | ES2460671T3 (pl) |
| PL (1) | PL1696947T3 (pl) |
| SI (1) | SI1696947T1 (pl) |
| WO (1) | WO2005058347A1 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8304386B2 (en) | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
| SG11201503879QA (en) | 2012-11-20 | 2015-06-29 | Opko Biolog Ltd | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| KR102527180B1 (ko) | 2014-12-10 | 2023-04-27 | 옵코 바이오로직스 리미티드 | 장기간 작용성 ctp-변형된 성장 호르몬 폴리펩타이드의 제조 방법 |
| KR102662956B1 (ko) | 2015-06-19 | 2024-05-03 | 옵코 바이오로직스 리미티드 | 장기-작용성 응고 인자 및 그의 제조 방법 |
| EP4303228B1 (en) | 2016-07-11 | 2026-05-27 | OPKO Biologics Ltd. | Long-acting coagulation factor vii and methods of producing same |
| RU2740060C1 (ru) * | 2020-02-14 | 2020-12-31 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ЮУГМУ Минздрава России) | Лекарственная форма для лечения и профилактики язвенного колита, содержащая пэгилированную липосомальную форму эритропоэтина в форме суппозиториев, обладающая противовоспалительным и иммуномодулирующим действием |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| DE3924705A1 (de) | 1989-07-26 | 1991-01-31 | Boehringer Mannheim Gmbh | Heterobifunktionelle verbindungen |
| SG88714A1 (en) | 1989-11-06 | 2002-05-21 | Cell Genesys Inc | Production of proteins using homologous recombination |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US5324650A (en) | 1990-03-20 | 1994-06-28 | E. I. Du Pont De Nemours And Company | Situ process for production of conjugates |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| AU1676992A (en) | 1991-03-18 | 1992-10-21 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| NZ245015A (en) | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| CA2101361A1 (en) | 1992-08-27 | 1994-02-28 | Robert A. Snow | Low diol polyalkylene oxide biologically active proteinaceous substances |
| NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| AU5773798A (en) | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
| WO1998041226A1 (de) | 1997-03-18 | 1998-09-24 | Roche Diagnostics Gmbh | Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| MEP90708A (hr) | 2000-05-15 | 2011-12-20 | Nova farmaceutska smješa | |
| WO2003025583A2 (en) | 2001-09-14 | 2003-03-27 | F. Hoffmann-La Roche Ag | Differential diagnosis of disorders of iron metabolism |
| US7459435B2 (en) * | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| US7459436B2 (en) * | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| CA2521979A1 (en) * | 2003-04-09 | 2004-10-28 | University Of Utah Research Foundation | Compositions and methods related to production of erythropoietin |
-
2004
- 2004-12-10 PL PL04803748T patent/PL1696947T3/pl unknown
- 2004-12-10 JP JP2006544291A patent/JP2007514673A/ja active Pending
- 2004-12-10 CA CA2549486A patent/CA2549486C/en not_active Expired - Lifetime
- 2004-12-10 WO PCT/EP2004/014105 patent/WO2005058347A1/en not_active Ceased
- 2004-12-10 CN CN200480039809XA patent/CN1901934B/zh not_active Expired - Lifetime
- 2004-12-10 DK DK04803748.5T patent/DK1696947T3/en active
- 2004-12-10 ES ES04803748.5T patent/ES2460671T3/es not_active Expired - Lifetime
- 2004-12-10 SI SI200432148T patent/SI1696947T1/sl unknown
- 2004-12-10 EP EP04803748.5A patent/EP1696947B1/en not_active Expired - Lifetime
- 2004-12-16 US US11/013,560 patent/US7459429B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2549486A1 (en) | 2005-06-30 |
| EP1696947A1 (en) | 2006-09-06 |
| JP2007514673A (ja) | 2007-06-07 |
| CN1901934A (zh) | 2007-01-24 |
| CA2549486C (en) | 2015-04-14 |
| DK1696947T3 (en) | 2014-03-17 |
| EP1696947B1 (en) | 2014-02-26 |
| US20050181986A1 (en) | 2005-08-18 |
| US7459429B2 (en) | 2008-12-02 |
| SI1696947T1 (sl) | 2014-05-30 |
| WO2005058347A1 (en) | 2005-06-30 |
| ES2460671T3 (es) | 2014-05-14 |
| CN1901934B (zh) | 2013-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1696947T1 (sl) | Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih | |
| ZA200804742B (en) | Compounds for the treatment of inflammatory disorders and microbial diseases | |
| IL191637A0 (en) | Compounds for the treatment of inflammatory disorders and microbial diseases | |
| IL172165A (en) | Fatty substances containing acidic groups and using them as a remedy for inflammatory diseases | |
| IL189578A0 (en) | Pyridine derivatives and their use in the treatment of psychotic disorders | |
| IL180759A0 (en) | Indazoles useful in treating cardiovascular diseases | |
| IL181706A0 (en) | The treatment of inflammatory disorders and pain | |
| IL175055A0 (en) | Combinations useful for the treatment of neuronal disorders | |
| EP1957462A4 (en) | NEW 2-AMINO-HETEROCYCLES USEFUL FOR THE TREATMENT OF ABETA-RELATED DISEASES | |
| IL181305A0 (en) | Combinations for the treatment of diseases involving cell proliferation | |
| EP1490044A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMABLE COMPONENTS | |
| IL175529A0 (en) | Methods and compositions for the treatment of metabolic disorders | |
| IL210091A0 (en) | TREATMENT OF TNFa RELATED DISORDERS | |
| AU2003228819A8 (en) | Combinations for the treatment of inflammatory skin disorders | |
| IL190969A0 (en) | Pyrazoles useful in the treatment of inflammation | |
| ZA200702421B (en) | Iron complex for use in the treatment and/or prevention of nutritional disorders | |
| IL175610A0 (en) | Methods and reagents for the treatment of inflammatory disorders | |
| EP1744740A4 (en) | PHENOXYALKYCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| GB0301395D0 (en) | Inflammatory disorder treatment | |
| GB0428170D0 (en) | Mono and Combination Therapy | |
| EP1805210A4 (en) | NOVEL PEPTIDES AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | |
| EP1877801A4 (en) | ANALYSIS AND THERAPY OF COPPER REGULATION | |
| GB0412793D0 (en) | Therapeutic product | |
| IL173068A0 (en) | Acute inflammatory condition treatment | |
| EP1997487A4 (en) | PRODUCT USED IN THE PREVENTION AND TREATMENT OF CARDIAC DISEASES, CANCER AND INFLAMMATORY DISEASES |